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Abstract
Fibrous dysplasia (FD) is sometimes accompanied by extraskeletal manifestations that can include any combination
of café-au-lait macules, hyperfunctioning endocrinopathies, such as gonadotropin-independent precocious puberty,
hyperthyroidism, growth hormone excess, FGF23-mediated renal phosphate wasting, and/or Cushing syndrome, as
well as other less common features. The combination of any of these findings, with or without FD, is known as
McCune-Albright syndrome (MAS). The broad spectrum of involved tissues and the unpredictable combination of
findings owe to the fact that molecular defect is due to dominant activating mutations in the widely expressed
signaling protein, Gsa, and the fact these mutations arises sporadically, often times early in development, prior to
gastrulation, and can distribute across many or few tissues.
The complexity can be mastered by a systematic screening of potentially involved tissues and cognizance that the
pattern of involved tissues is established, to some degree, in utero. Thorough testing allows the clinician to
establish, often times at presentation, the full extent of the disease, and importantly as well what tissues are
unaffected. Treatment and follow-up can then be focused on affected systems and a meaningful prognosis can be
offered to the patient and family. The authors outline screening and treatment strategies that allow for effective
management of the extraskeletal manifestations of FD.
Introduction
The original extraskeletal manifestations of fibrous dys-
plasia (FD) reported by McCune [1] and Albright [2]
were café-au-lait spots, precocious puberty, and
hyperthyroidism. With time a number of manifestations
were added to the spectrum of findings that could be
seen in association with FD. These included growth hor-
mone (GH) excess [3], hypercortisolism [4], hypopho-
sphatemia/osteomalacia [5], hepatic involvement [6],
cardiac involvement [7], and others [8].
NIH cohort
To evaluate the extraskeletal manifestations observed in
patients with FD we reviewed all of the patients seen at
the National Institutes of Health over the last 24 years.
The evaluation included physical examination, imaging
studies (skeletal survey, head CT, nuclear medicine bone
scan, ultrasound of the thyroid and gonads, and MRI of
the pituitary), biochemical studies of skeletal metabolism
and endocrine axes, and when available mutation analy-
sis of affected tissue. There have been 140 patients eval-
uated at the time of this review. Patients have been
followed from <1 – 24 years.
Prevalence of extraskeletal manifestations
The relative prevalence of findings in MAS patients in
t h eN I Hc o h o r ta r es h o w ni nT a b l e1 .W h i l et h e s ed a t a
probably reflect the relativep r e v a l e n c eo fe a c ho ft h e s e
findings, it is also likely that the NIH cohort represents a
more severely affected group of patients than is typically
found in clinical practice. Therefore the likelihood of an
individual patient with FD having a given manifestation
is probably lower than shown here.
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findings seen in association with FD as part of the
McCune-Albright syndrome, we have observed a num-
ber of other findings in associated with the disease.
These are shown in Table 2.
Timing of appearance of extraskeletal
manifestations
An important consideration in terms of patient/family
counseling and the ability to give a prognosis for patients
with FD/MAS is when are the manifestation of the disease
established, and its corollary question, when is it safe to
say that a given aspect of the disease will not manifest.
The answer to these questions depends upon early and
complete screening to establish if a tissue is affected or
not. Whether or not a tissue is affected is also important
for long term follow-up. In a study by Hart et al., using
the combined tools of
99Tc-MDP bone scans, skeletal sur-
veys, and CT scans of the skull, we were able to establish
that the majority of skeletal disease, depending on the site,
was established roughly between 3 – 10 years of age.
Almost all sites of disease that eventually became clinically
significant were present by the age of 5 (Table 3). In most
cases, this means that almost all clinically significant dis-
ease will be present at the time of the first evaluation.
While not as well studied, this same pattern of the early
establishment of disease is probably true for the extraske-
letal manifestations. For example, by ultrasound, the
most sensitive tool for the detection of thyroid disease,
involvement of the thyroid, or lack thereof, is established
at the first evaluation and persists over many years of fol-
low-up. These findings are consistent with our current
understanding of the molecular genetics and embryology
of the disease. The manifestations of FD/MAS are due to
somatic activating mutations in the GNAS gene, some-
times referred to as the gsp oncogene, which codes for
the protein Gsa that is involved in intracellular cAMP
production [9,10]. To result in a disease that involves
cells derived from all three germ layers (ectoderm – e.g.
skin, mesoderm – e.g. bone, and endoderm – e.g. thyr-
oid), the mutation must occur very early in development.
Thus the “map” of involved tissues, many of which will
not become clinically evident for some time, are deter-
mined in utero. With the exception of Cushing’ss y n -
drome, phosphaturia, and precocious puberty, in the vast
majority of cases once a manifestation is present, it exists
throughout life. Figure 1 depicts graphically what one
can expect, as far as the age at which clinically significant
disease becomes evident.
Café-au-lait spots
When present, the café-au-lait spots that can be seen in
MAS are typically the first manifestation of the disease,
usually appearing either at or shortly after birth. As such,
they can be an early clue to the diagnosis. They have been
Table 1 Prevalence of major findings in the NIH cohort of
patients with fibrous dysplasia/McCune-Albright
syndrome
Clinical finding % patients
1
Fibrous dysplasia 98
Café-au-lait spots 66
Gonadal abnormalities
Male: (ultrasound)
2 70
Female: precocious puberty 50
Thyroid abnormalities
Abnormal ultrasound (U/S) 66
Hyperthyroid + abnormal U/S 28
Renal phosphate wasting 43
Hypophosphatemia 10
Growth hormone excess 21
Cushing’s syndrome 4
1 n = 140; 58 males, 82 females
2 detected on ultrasound
Table 2 Prevalence of less common findings in the NIH
cohort of patients with fibrous dysplasia
Other clinical findings % patients
1
Gastrointestinal 7
History of hepatitis
2 4
Reflux
2 5
Pancreatitis
2 3
Polyps
3 5
Cardiac 6
Tachycardia
4 4
Aortic root dilatation (GH excess)
5 2
Hematologic 1
Platelet dysfunction 1
Cancer 4
Thyroid
6 1
Breast
6 2
Bone
6 1
Testicular
6 1
Hyperparathyroid 1
Neuropsychiatric 9
1n = 140; 58 males, 82 females,
2appeared in childhood, common causes
excluded,
3atypical, upper GI tract polyps, myxomatoid pathology more
common,
4unexplained/not associated with hyperthyroidism,
5only seen in
patients with growth hormone excess,
6all tumors bear Gsa mutation,
adjacent normal tissue mutation negative.
Table 3 Age at which FD lesions are established by site
Percent of lesions
present
Craniofacial Axial Extremity Total
body
50% NA 7.4 4.9 5.7
75% NA 11.7 9.6 10.7
90% 3.4 15.5 13.7 15
NA = not applicable
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Page 2 of 14classically described as having a “coast of Maine” border,
which refers to the jagged appearance of the Maine coast-
line as it appears on maps. While this is usually the case, it
is not always true. Examples of café-au-lait spots seen in
M A St h a tb o t hc o n f o r mw i t ha n dd e f yt h i sd i c t u ma r e
shown in Fig. 2. Likewise, café-au-lait spots found in MAS
usually show some association with (“respect”) to the mid-
line. Again, while this is often the case, there are frequent
exceptions. Examples of these can be seen in Fig. 2 C & E.
While these spots do cross the midline, they retain some
association to the midline.
Contrary to what has been previously reported, we have
not observed a correlation between the size of the spots
and the extent of the disease. Nor have we observed a cor-
relation between side of the body on which the spot is
found and the side of the body on which the FD is found.
The café-au-lait spots seen in association with FD are
the result of gsp-bearing melanocytes in which the
mutation brings about c-AMP-mediated tyrosinase gene
activation and melanin production in mutation-bearing
cells [11]. There are no well-defined effective treatments
for the hyperpigmentation seen in MAS. Attempts to
bleach areas of hyperpigmentation usually leave an area
of under pigmentation, which is usually unsatisfying to
the patient. A single report of the efficacy of Q-switched
ruby laser in the treatment of the café-au-lait spots of
MAS has been reported [12], but further evidence of
efficacy is necessary before such a treatment can be rou-
tinely recommended.
Precocious puberty
Introduction
Precocious puberty is one of the defining manifestations
of McCune-Albright syndrome (MAS) (10). It arises due
to autonomous gsp-mediated gonadal function in cells
harboring the GNAS activating mutation. Thus, it is char-
acterized as a form of peripheral precocious puberty, in
contrast to the early hypothalamic-pituitary-gonadal
(HPG) axis activation designated as central precocious
puberty. Although it might theoretically be expected to
affect girls and boys equally, precocious puberty in chil-
dren with MAS is far more common in girls, in whom it
is typically both the presenting feature as well as the one
that ultimately leads to the diagnosis being made. As the
clinical characteristics, diagnosis and treatment are dis-
tinctly different, precocious puberty in girls will be con-
sidered separately from precocious puberty in boys with
MAS.
Fibrous dysplasia
Café-au-lait
Precocious Puberty      
Thyroid
Phosphaturia
Growth Hormone Excess
Cushings
0  5  10 15 20 30 50ї
Age  pre-clinical 
clinically evident 
spontaneous resolution possible 
persistent abnormal menses 
Figure 1 The relative age at which any given aspect of the disease becomes clinically evident is depicted by a solid black bar. Preclinical disease
is depicted by gray bars, and ages during which spontaneous resolution is possible for Cushing’s disease and phosphaturia are shown in open
bars. The period of time during which abnormal menstruation can be expected is depicted by the stippled bar.
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The typical presentation of precocious puberty in girls
with MAS consists of vaginal bleeding. Typically pain-
less, sometimes profuse, and usually accompanied by the
development of breast tissue; this represents withdrawal
bleeding following the resolution of large unilateral
estrogen-producing ovarian cysts [11]. Since the cysts
are usually asymptomatic, their presence often goes
unrecognized until the bleeding occurs. On physical
exam, most girls are noted to have mild breast enlarge-
ment at a Tanner II or III stage of development. If the
child does not come to attention until after the
A 
B 
C 
D  E 
Figure 2 Representative Café-au-lait Spots Seen in McCune-Albright Syndrome. A spectrum of spots is shown; Panels A & B demonstrate
“classic” spots that both respect the midline and display “coast of Maine” borders. Panel C shows a very unusual spot seen in a child with MAS
and neonatal Cushing syndrome. While the spot respects the midline, the borders are smooth and the spots alternate from left to right in a
harlequin pattern. Panel D depicts a very large spot with relatively smooth borders seen in a patient with relatively little FD. Panel E
demonstrates a spot that clearly does not respect the midline.
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Page 4 of 14resolution of the initial episode, the breast tissue may
have resolved and on casual inspection involuted breast
tissue may be missed. Similarly, the finding of obvious
and classic café-au-lait macules in girls with MAS is
quite variable and, even if present, their significance
may go unrecognized. Therefore, it is not unusual for
girls to present initially to an emergency department or
primary care clinic and have the treating physicians fail
to include MAS in the differential diagnosis. As some of
the clinical and radiographic findings overlap with those
of juvenile granulosa cell tumors, girls with MAS some-
times end up undergoing unnecessary oophorectomy for
a presumed ovarian tumor [12]. Ideally, vaginal bleeding
in a prepubertal girl should always prompt consultation
with a pediatric endocrinologist so that, in the case of
MAS, unneeded loss of the ovary can be prevented.
In addition to a history and physical exam, the initial
evaluation of precocious puberty in a girl with suspected
MAS consists of laboratory and radiographic studies. Clas-
sic biochemical findings include elevated estradiol and
estrone levels, which are many-fold higher than prepuber-
tal values, in association with suppressed gonadotropins.
Pelvic ultrasound typically reveals a large unilateral ovarian
cyst which may be hemorrhagic and appear to have mixed
cystic and solid elements. As would be predicted, extreme
asymmetry in ovarian volumes between the two sides is
the norm, in striking contrast to the symmetrical ovarian
enlargement emblematic of central precocious puberty
[13]. If seen after the initial episode, growth parameters
and bone age x-ray are often normal. The diagnosis of
MAS is typically made clinically on the basis of classic fea-
tures, including café-au-lait pigmentation. A bone scan to
look for fibrous dysplasia and screening for other MAS-
associated endocrinopathies are important elements of the
diagnostic work-up. However, isolated precocious puberty
without any other identifiable abnormalities may also be
seen in girls with MAS [14]. Serial ultrasounds, if indi-
cated, will reveal a gradual resolution of the ovarian cyst
over several weeks.
The natural history of precocious puberty in girls with
MAS is extremely variable. The first episode can occur as
early as during the first few months of life or as late as
age 6 or 7 years. Likewise, subsequent episodes are highly
unpredictable. While many girls have extended periods
of quiescence that last for several years, others have fre-
quent bouts of vaginal bleeding along with progressive
breast development followed by the onset of pubic and
axillary hair and adult body odor. As is seen with all
forms of significant sex steroid exposure during the pre-
pubertal years, linear growth acceleration and advanced
skeletal maturation also ensue. Unfortunately, there is no
way to predict exactly when the next episode of preco-
cious puberty will occur, which can contribute to the
anxiety experienced by parents when this complex
disorder is diagnosed. Similarly, the precocious puberty
flare-ups themselves vary in severity. In contrast to the
typical vaginal bleeding, some girls are noted to simply
have periodic waxing and waning of breast enlargement
without overt bleeding.
Historically, the prevailing notion was that the HPG
axis would override autonomous ovarian function in girls
with MAS once physiologic puberty was underway. How-
ever, this has given way to the recognition that women
with MAS continue to experience intermittent autono-
mous ovarian function marked by the development of
large unilateral ovarian cysts and irregular vaginal bleed-
ing [15]. This has the potential to interfere with normal
ovulatory function with subsequent implications in terms
of fertility [16]. However, in most cases adults with MAS
have been able to have children, even if it may take
longer than normal to conceive.
Management
Clinical management of precocious puberty in a girl with
MAS consists initially of observation. Girls with only
sporadic and infrequent vaginal bleeding often do not
need to be treated. In the subset of girls with a progres-
sive form of precocious puberty, pharmacologic interven-
tion is recommended in order to prevent early epiphyseal
fusion and augment adult height. However, other than
anecdotal case reports, to what extent height is compro-
mised and whether intervention ameliorates this, is not
well established. As is the case for all aspects of MAS,
both the rarity and heterogeneity of the disease present
significant challenges to rigorous investigation.
Current treatment of precocio u sp u b e r t yi ng i r l sw i t h
MAS revolves around the use of anti-estrogens. Two
basic strategies exist. The first relies on interfering with
estrogen biosynthesis through the use of an aromatase
inhibitor [17], while the second aims to blunt the effects
of estrogen at the level of the end-organ through receptor
blockade. To date, small uncontrolled trials have been
conducted with first, second and third generation aroma-
tase inhibitors. Experience with the first generation
agent, testolactone, was ultimately marred by sub-optimal
efficacy as well as issues with compliance [18]. Investiga-
tion of the second generation aromatase inhibitor, fadro-
zole, was abandoned following concerns about adrenal
suppression [19]. Among the third generation com-
pounds, anastrozole has been deemed ineffective [20].
Letrozole, however, was found to result in a significant
decrease in rates of skeletal maturation in a small num-
ber of girls treated for 3 years, although mean ovarian
volumes were unchanged [21]. Most girls also experi-
enced a decrease or cessation in vaginal bleeding while
on letrozole, although one subject who had entered sec-
ondary central precocious puberty developed a large cyst
with subsequent ovarian torsion. Treatment with the
Collins et al. Orphanet Journal of Rare Diseases 2012, 7(Suppl 1):S4
http://www.ojrd.com/content/7/S1/S4
Page 5 of 14selective estrogen receptor modulator, tamoxifen, has
also been studied in a group of girls with MAS treated
for one year. In addition to a significant decrease in vagi-
nal bleeding, tamoxifen resulted in an improvement in
growth velocity and bone age advancement [22]. Despite
these positive results, the finding of increased uterine and
ovarian volumes in the girls treated with tamoxifen
represents a potential safety concern that to date remains
unresolved. Lastly, preliminary results from a prospective
study utilizing the pure estrogen receptor blocker, fulves-
trant, are available. A decrease in the median number of
vaginal bleeding days as well as in the average rate of ske-
letal advancement in 30 girls treated for one year was
seen [23]. Thus, relatively comparable efficacy has now
been observed with several agents used in the treatment
of precocious puberty in girls with MAS, although none
have been perfect and none have emerged as being
clearly superior to the others. Studies comparing avail-
able medications in a head to head fashion are needed.
Precocious puberty in boys
There are several important differences between preco-
cious puberty in girls with MAS and its counterpart in
boys. One distinction is that precocious puberty is very
rare in affected boys, who are diagnosed with MAS far
more often due to the finding of bone disease or café-
au-lait pigmentation. An additional dissimilarity is that
the precocious puberty, when present, is more likely to
be subtle and indolent in boys. Lastly, the activating Gsa
mutation and resulting gonadal hyperfunction have been
reported to be limited to the testicular Sertoli cells in
several boys with MAS. This has resulted in either uni-
lateral or bilateral macroorchidism without precocious
puberty [24][25][26][27]. Interestingly, many of these
cases have also been associated with testicular micro-
lithiasis, which has also been identified in males of all
ages with MAS [28][29]. Due to its extreme rarity, only
anecdotal case reports detailing treatment options for
precocious puberty in boys are available. The most com-
mon approach employs combination therapy in the form
of an androgen receptor blocker such as spironolactone,
flutamide or cyproterone acetate along with a com-
pound that interferes with sex steroid synthesis such as
ketoconazole or an aromatase inhibitor [30]. On princi-
ple, the same strategies used to treat boys with other
forms of peripheral precocious puberty such as familial
male precocious puberty, would be efficacious in the
setting of MAS. One such example is the combination
of bicalutamide, a pure androgen receptor blocker, with
the third generation aromatase inhibitor anastrozole
[31]. Similar to what has been reported in women with
MAS, fifteen year follow-up in a boy with MAS and
history of precocious puberty indicated persistent auton-
omous testicular hyperfunction and suppressed
gonadotropins [32]. Although inhibin B was undetect-
able, active spermatogenesis occurred and was seemingly
unaffected.
Thyroid
At the NIH approximately 2/3 of the patients had invol-
vement of the thyroid when assessed by the most sensi-
tive method for assessing thyroid involvement,
ultrasound [13]. Only about 1/2 of the patients who had
involvement of the thyroid detected on ultrasound had
frank hyperthyroidism, as evidenced by a suppressed
TSH. As in every aspect of MAS, the thyroid findings
e x i s ta l o n gas p e c t r u mf r o ma ni s o l a t e da r e as e e no n
ultrasound with no clinical findings to patients with
obvious goiters, and hyperthyroidism that is unable to be
adequately controlled with medications and requires
either surgery or ablation. The presence of the gsp muta-
tion in thyroid tissue results in ligand-independent acti-
vation of the TSH/G-protein/cAMP pathway, which is
known to result in both hyperplasia and hyperfunction
[14]. Additionally, the gsp mutation results in increased
thyroxine (T4) to triiodothyronine (T3) conversion,
which accounts for the T3-dominant biochemical pheno-
type of MAS patients with hyperthyroidism [13].
It is important to diagnose hyperthyroidism in MAS, as
hyperthyroidism can advance bone age, which may
already be a problem in children with precocious pub-
erty, lead to or exacerbate osteoporosis, and cause a
plethora of other metabolic derangements. Diagnosis is
usually straight forward and involves the measurement of
TSH and thyroid hormones, T3 and T4. It is not uncom-
mon to have a normal T4 in the setting of a suppressed
TSH. This apparently incongruous finding is clarified
when T3 is measured and found to be high. In patients in
whom the only abnormality is an abnormal ultrasound, it
is important to continue to check TSH and thyroid hor-
mone periodically as the development of frank hyperthyr-
oidism may occur later. The ultrasound findings in MAS
are usually a mixture of mostly cystic with some solid
lesions (Fig. 3) [13,15].
Hyperthyroidism in MAS usually responds quite well
to thionamides. However, since hyperthyroidism is one
of the aspects of MAS that persists, it is often desirable
for the patient to undergo definitive treatment, which
usually means surgery or ablation with radioactive
iodine. Surgery may be difficult in very small children,
and is therefore recommended to delay surgery in small
children.
Hypophosphatemia
While rickets in association with FD was originally
reported in 1968 [5], it was not until 2001 that it was evi-
dent the cause was a circulating phosphaturic hormone,
s i m i l a rt ow h a ti ss e e ni nt h einherited forms of rickets
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be the cause [17]. FGF23 is overproduced by FD tissue,
such that the greater the disease burden, the higher the
FGF23, the greater the degree of renal phosphate wasting,
and the lower the serum phosphorus (Fig. 4). Therefore,
significant hypophosphatemia is only seen in patients
with a very significant skeletal burden of FD. It has also
been observed that, unlike many other extraskeletal man-
ifestations aspects, renal phosphate wasting can sponta-
neously resolve as patients age. This probably reflects
intrinsic changes that have been observed at the tissue
level and characterized as “normalization” [18].
The clinical sequelae and significance of hypophospha-
temia are an earlier age of first fracture, more fractures,
and bone pain [19]. There are no controlled studies to
support that treating hypophosphatemia decreases frac-
tures or improves pain, but observation of treated
patients suggests that treatment may improve outcomes.
Treatment of hypophosphatemia is the same as in other
FGF23-mediated phosphate wasting disorders, and
involves the use of phosphate and active vitamin D (calci-
triol or alfacalcidiol). Details for this treatment regimen
can be found elsewhere [8,20].
Growth hormone excess
Growth hormone excess in association with FD is the
manifestation of gsp mutation in the anterior pituitary
[21]. It is always accompanied by skull base FD, and
the vast majority of patients also have hyperprolactine-
mia. The usual presenting sign is increased growth
velocity. However, if GH excess is accompanied by pre-
cocious puberty, the clinical sign of increased growth
velocity can be obscured by the increase in growth
velocity that is seen as part of precocious puberty.
Likewise, if a patient with precocious puberty achieves
his/her predicted height, this can be a sign of GH
excess, as precocious puberty should have resulted in
short stature. For this reason, it is important to do
laboratory screening for GH excess in patients with
FD, as the clinical evaluation can be confounded by
concomitant hormonal excess and make the clinical
exam difficult to interpret.
Probably the most important reason to diagnose GH
excess in association with FD is that it is associated with
an increase in morbidity, specifically in the craniofacial
region. GH excess in FD is associated with macroce-
phaly and vision loss [22,23].
Figure 3 Clinical and ultrasound findings of thyroid involvement in FD/MAS. Panels A & B demonstrate the findings in a 9-year-old girl with
MAS and hyperthyroidism. A goiter is clearly seen on inspection (A) and the ultrasound (B) shows the typical cystic (Swiss cheese) appearance
that seen in MAS thyroids. Panels C & D demonstrate the findings of a 30-year-old woman with MAS. While no goiter was evident on inspection,
nor was one obvious on palpation, the ultrasound clearly demonstrated the typical findings seen in ultrasounds of patients with MAS and
thyroid involvement. Adapted from reference [13.]
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Non-suppressible serum GH on an oral glucose tolerance
test (OGTT) is diagnostic of GH excess [21]. However, in
subtle disease the results of the OGTT can be equivocal,
especially in young children [24]. In these difficult cases,
frequent (every 20 min) overnight sampling may be of
utility. Children with GH excess will fail to have any
intervals when the GH value is below 1 ng/ml. As stated
previously, almost all patients with FD/MAS- associated
GH excess also have an elevate prolactin. Therefore, the
prolactin level can be an additional tool in either con-
firming or excluding the diagnosis of GH excess.
Our most recent analysis of the NIH cohort of
patients with GH excess indicates that early diagnosis
and treatment of GH excess may prevent GH excess-
associated morbidity, specifically vision loss.
Treatment of GH excess in FD/MAS is almost exclu-
sively confined to medical treatment. Usually, due to the
massive expansion of the skull base with FD, which
includes obliteration of the sphenoid sinus, the traditional
transphenoidal approach to the pituitary is either not
possible or extremely difficult. An additional important
consideration if surgery is contemplated, is the fact that, in
spite of what may appear as a single adenoma on pituitary
imaging, the entire anterior pituitary is usually infiltrated
with areas of herplastic and/or adenomatous somatotrophs
and somatolactotrophs. The implications of this finding
are that surgical cure of GH excess in FD/MAS will
require a complete hypophysectomy – a treatment that, if
it is to be embarked upon, is probably best delayed until
young adulthood. Given that treatment doses of radiation
directed at FD are associated with an increase in malignant
transformation [25,26], radiation is rarely an acceptable
approach.
Treatment
The drug with which there is the longest experience in
treating FD/MAS-related GH excess is octreotide
[21,27-29]. It is usually effective in lowering serum GH
and IGF-1 levels. In growing children, the goal of treat-
ment is to decrease the IGF-1 to the middle of the normal
range (IGF-1 Z-score = 0). In mature patients, the goal is
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Figure 4 Panel A demonstrates the relationship and significant negative correlation between serum FGF23 and the degree of phosphate
wasting, supporting the concept that FGF23 is responsible for the phosphate wasting that can be seen in association with FD. Panel B depicts
the relationship and significant positive correlation between the serum FGF23 and the skeletal burden of FD, which supports the hypothesis that
the FD tissue is the source of FGF23. Panels C&D are low and high power views, respectively, of in situ hybridization studies using probes for
FGF23 that demonstrate that FD tissue demonstrates high levels of FGF23 transcripts. Panels E&F show high levels of FGF23 transcripts in bone
from control, normal bone; E osteocytes and F osteoblasts in healing fracture callus. FD = fibrous dysplasia, wb = woven bone, b = bone,
double arrows designate FD stromal cells, arrow heads designate osteocytes, single arrows designate osteoblasts. Adapted from reference [17].
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receptor antagonist, pegvisomant, has also been shown to
be effective in treating MAS patients with GH excess
[30,31]. Which drug is superior is not known. In some
patients a combination of both octreotide and pegviso-
mant is necessary to achieve control, and in a small minor-
ity of patients not even the combination is effective. This is
the group that should be considered for surgery and/or
radiation. We have attempted to treat the GH excess in
MAS with the dopamine agonist, cabergoline as a single
agent in several cases, but had no success (unpublished
data).
The hyperprolactinemia that usually accompanies GH
excess in MAS is not affected by treatment with octreo-
tide or pegvisomant, but is almost always effectively
controlled with dopamine agonists, such as cabergoline
or bromocriptine.
Cushing’s syndrome
Cushing’s syndrome is the rarest of endocrine abnormal-
ities found in MAS [32]. It always occurs in the neonatal
period, which parallels the involution of the fetal adrenal
gland and may suggest a differential effect of the gsp
mutation on the fetal adrenal, which is supported by the
fact that both glands are always involved [33]. Cushing’s
syndrome is one of the few aspects of MAS that is asso-
ciated with increased and early mortality. Most of the
early mortality associated with Cushing’ss y n d r o m ei n
MAS is due to opportunistic infections, and highlights
the importance of prophylactic treatment, notably for
Pneumocystis species.C u s h i n g ’s syndrome usually only
occurs in patients with MAS with significant involvement
of multiple other tissues. Patients with Cushing’s are also
more likely to have many of the manifestations men-
tioned in Table 2.
A review of all the published cases of Cushing’ss y n -
drome in MAS [32] listed the following signs and symp-
toms: small for gestational age (50%), round facies (67%),
failure to thrive (60%), hypertension (33%), nephrocalcino-
sis (30%), hirsutism (27%), hyperglycemia (20%), and linear
growth arrest (10%). While it is clearly documented that
some cases of Cushing’s syndrome can resolve sponta-
neously [34], it is impossible to predict in which patients
this will occur. Therefore making the diagnosis necessi-
tates treatment. This usually involves surgical removal of
diseased adrenal glands. However, medical treatment is
sometimes able to lower ser u mc o r t i s o lt on o r m a lo r
lower. Since many children with MAS and Cushing’s
syndrome also have evidence of a cholestatic hepatitis, the
often effective drug ketoconazole is avoided due to it is
potentially hepatotoxicity. Metyrapone is frequently effec-
tive. The initial dose is 300 mg/m2/day. It may be
increased to as high as 1200 mg/m2/day, as needed. In
particularly sick children, medical treatment with
metyrapone may buy time until the child is healthy
enough for surgery.
Long term sequelae of Cushing’ss y n d r o m ei nM A S
include a significantly increased prevalence of cognitive
disorders, including specific learning or speech disor-
ders, or global developmental delay and speech apraxia.
Other extraskeletal manifestations
The additional less common extraskeletal manifestations
associated with MAS are outlined in Table 2. Some will
be discussed below. Hepatitis, when it occurs, is more
pronounced after birth, has laboratory manifestations
consistent with cholestasis, progressively wanes with
age, usually persists into adulthood, albeit mild, and is
virtually never associated with a functional defect in
synthesis of important hepatic factors [6].
Gastrointestinal reflux
Gastroesophageal reflux is infrequently seen in MAS, and
primarily in patients with multiple extraskeletal manifes-
tations. It usually manifests in childhood and can be a
source of significant discomfort to patients. The etiology
is unknown, but is presumed to be incompetence of the
lower esophageal sphincter from unknown mechanisms.
Hyperacidity does not appear to be the primary issue.
Treatment is usually medical and involves the use of his-
tamine blockers or proton pump inhibitors. It has not
been reported to be associated with metaplasia of the
lower esophagus (Barrett’s esophagus).
Gastrointestinal polyps
Gastrointestinal polyps, especially in unusual locations
(gastric and duodenal) and of significant size have been
observed in association with MAS (personal observations,
MTC). They can become clinically significant if they
reach a size that can cause obstruction. The long term
significance and malignant potential is unknown,
although reports of a role of activating mutations of Gsa
have been seen in association with gastrointestinal malig-
nancies [35]. To date, no gastrointestinal malignancies
have been reported in association with FD/MAS.
Pancreatitis
Idiopathic pancreatitis has been observed in patients
with FD/MAS. The prevalence observed in the NIH
(approximately 3%) is greater than would be expected in
an unselected population, however a direct association
with MAS has not been demonstrated and there are no
known associations between gsp mutations and a predis-
position to pancreatitis.
Cardiac
There are several cardiac abnormalities that have been
reported in association with FD/MAS. These include
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aortic root dilatation. While much has been made of sud-
den death as part of MAS [7,36], and the fact that the gsp
mutation was found in cardiac tissue of children who had
sudden death, evidence that the cause of death was car-
diac, and/or that the gsp mutation played a role is lack-
ing. While patients with FD/MAS are clearly at cardiac
risk due to hyperthyroidism and other endocrine
abnormalities, the risk for sudden cardiac death is prob-
ably minimal if any.
Tachycardia
Tachycardia can be seen in patients with FD/MAS who
are hyperthyroid [13,15]. Tachycardia in the absence of
hyperthyroidism (unexplained tachycardia) was seen in
approximately 4% of the NIH cohort of patients with FD/
MAS. There are at least two possible explanations for this;
it could represent the presence of the gsp mutation in the
heart, or it could represent the physiologic response to
increased demand placed on the heart due to extensive
FD, which is a very vascular tissue. The two explanations
are not mutually exclusive. In fact, more extensive extra-
skeletal involvement is usually seen when there is exten-
sive skeletal involvement. Therefore, cardiac gsp,w h i c h
has been demonstrated [7] may be more likely to be seen
in patients with extensive disease. All of the patients with
unexplained tachycardia in the NIH cohort had extensive
FD. Therefore, it is not clear if the cause was primary
cardiac (gsp mutation in the heart), or a secondary, physio-
logic response to increased demand placed on the heart by
extensive bone disease. How to treat these patients is a
conundrum. Untreated pathologic tachycardia, as can be
seen in hyperthyroidism, can lead to a cardiomyopathy
and heart failure. However, inappropriate suppression of
physiologically-induced tachycardia that can be seen as
part of increased demand could also lead to heart failure.
In one patient with total skeletal involvement with FD an
effort to suppress demand (vascularity) by aggressive
bisphosphonate treatment had no effect – at least in part
because it did not appear to have any effect on vascularity.
To date, we have opted not to treat these patients with
beta blockers. However, they are monitored closely with
cardiac echocardiogram and cardiac MRI for any early
signs of decompensation suggestive of impending heart
failure. Any sign of decompensation will ben and indica-
tion for treatment. Thus far, with a follow-up of almost 10
years there has not been any decompensation.
Aortic root dilatation
We have observed dilatation of the aortic root in several
patients with GH excess in the NIH cohort. We have
made the assumption that this is the direct effect of GH
excess on the heart, as this has been reported in associa-
tion with acromegaly [37]. In one of the patients the
aortic root dilatation is clinically significant. In this sub-
ject, who had many years of untreated GH excess and
extensive morbidity due to untreated GH excess, the
disease led to aortic root dilatation, marked aortic valve
insufficiency, atrial dilatation and atrial fibrillation [54].
In the other subjects who started treatment at an earlier
age, there has not been any progression and there is no
associated cardiac morbidity.
Platelet dysfunction
Platelet dysfunction has also been reported in associa-
tion with FD and it has been suggested this may play a
role in the extensive bleeding that can be seen during
operations on FD tissue [38]. However, FD tissue is also
extremely vascular and it is difficult to determine
whether platelet dysfunction may contribute to bleeding
beyond what is expected from vascularity. Whether or
not all patients should be screened for platelet dysfunc-
tion is not clear. However, in subjects with a history of
difficult to control bleeding, platelet dysfunction should
be considered preoperatively.
Cancer
The cancers that have been reported in association with
FD/MAS, and in which the presumably etiologic gsp muta-
tion has been identified in the malignant tissue, include
malignant transformation of FD, thyroid, and breast. In
addition to these, we have received personal communica-
tions of cancers of the testes and lung; however these have
not been checked for gsp mutation. The activating muta-
tions that cause FD/MAS were given the designation as an
oncogene (gsp) because they were originally found as the
cause of benign endocrine adenomas [39]. However these
diseases are almost invariably benign and suggest that for
malignant transformation to take place additional muta-
tions probably arise in addition to gsp mutations. This
concept is supported by the finding that gsp mutations are
not uncommonly seen as part of the genomic landscape of
common cancers such as breast and colon, mutations in
many other genes known to be associated with cancer
development are found [35]. This concept is further sup-
ported by the detailed chromosomal and genetic analysis
of a cell line that was derived from a patient with FD in
whom the FD transformed into a malignant fibrous histio-
cytoma [40]. In addition to the expected gsp mutation
there were multiple structural and numerical abnormal-
ities of chromosomes with a large number of unidentifi-
a b l ec h r o m o s o m e sa sw e l la sap 5 3m u t a t i o ni ne x o n7
accompanied by loss of heterozygosity in the counterpart
allele.
Bone cancers
There are a number of very good reviews that catalogue
the reports of cases of FD that have transformed to
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among others osteosarcomas, fibrosarcoma, chondrosar-
coma, and even a malignant mesenchymoma that
demonstrated multiple cell types all with malignant fea-
tures [25,26,41-45].
It is difficult to determine what the risk of malignant
transformation in FD is from the published literature.
Series and centers report the number of cases of cancers,
but it is difficult to know what the appropriate denomi-
nator is to determine the prevalence, and/or it is difficult
to judge what the impact of the referral bias is for that
given institution and that series. For example, a review of
the Mayo Clinic data identified 28 cases of malignancy
out of 1122 total cases, for a prevalence of about 2% [46].
This would be considered by most experts to be a high
estimate of the risk of malignant transformation of FD
and probably reflects a referral bias of the institution for
bone cancers. In the NIH cohort of approximately 140
patients with disease on the more severe end of the spec-
trum, we have seen only one case in over 20 years of
experience, for a prevalence of <1%.
Malignant transformation is suggested by an expand-
ing, previously stable lesion, new focal pain, with the
radiographic hallmark being a breach of the bone cortex
with the extension of a soft tissue mass beyond the
cortex.
In terms of other factors that may impart additional
risk (or protection), there is little guidance in the litera-
t u r e .H e r et h ep r o b l e mi st h a ti ti sn o tc l e a rt ow h a t
extent any individual patient has been studied to identify
additional risk factors. It is possible that the presence of
GH excess may add additional risk for malignant trans-
formation. The two cases of breast cancer and the single
case of malignant transformation of FD observed in the
NIH cohort all occurred in women with GH excess. In
addition, while not systematically studied, there is a sense
from the literature in the patients who appear to have
been thoroughly investigated, that GH excess may impart
additional risk for the malignant transformation of cra-
niofacial FD [47-50], as well as for bone cancer in general
[51,52].
Thyroid
Thyroid cancer has been observed in two patients in the
NIH cohort (prevalence approximately 1.3%). Support for
the fact that this was a true relationship between the pre-
sence of the gsp mutation and thyroid cancer was the fact
that in both cases the mutation was found in the neoplas-
tic tissue, but not in the adjacent normal tissue [53].
Further support is lent by the fact that in both cases
there were unusual features further suggesting an asso-
ciation, specifically young age and tumor type (clear cell
carcinoma, which is a rare variant of thyroid cancer that
has been reported in association with hypothyroidism-
associated goiter, in which case there will be increased
TSH/Gsa/cAMP signaling).
Diagnosis of cancer within the thyroid of a patient with
MAS is difficult, given that the gland is often diffusely
abnormal and it is difficult to identify malignant changes
on this diffusely abnormal background (Fig. 3). Suggestive
clinical findings are an expanding firm nodule, and/or an
expanding solid nodule on ultrasound. If these findings
are present, a fine needle aspiration should be performed
with cytological examination to exclude malignant find-
ings. Given that definitive treatment of hyperthyroidism,
which includes thyroidectomy, is often recommended, one
should have a low threshold to perform a thyroidectomy
on a fine needle aspiration specimen that is inconclusive.
Breast cancer
Two cases of breast cancer have been reported in associa-
tion with FD/MAS [54,55]. In neither case did the inves-
tigators examine the malignant tissue for gsp mutations,
so it is not possible to determine whether or not the
development of cancer in these women was directly
related to the underlying gene defect. In both cases, the
women had had precocious puberty, and since prolonged
estrogen exposure is known to be a risk factor for the
development of breast cancer, it is reasonable to assume
that precocious puberty as part of MAS can be consid-
ered a risk factor for breast cancer. We have seen two
cases of breast cancer in the NIH cohort; both women
presented before the age of 30 and both women had had
precocious puberty and GH excess. (One of these
patients was the patient reported by Huston et al.,[55])
While it is enticing to consider GH excess as an addi-
tional risk factor for the development of breast cancer in
MAS, it is impossible to say at this point. In fact, whether
or not there is a relationship between breast cancer and
sporadic GH excess is not clear [56].
Testicular cancer
While there are no reported cases of testicular cancer in
men with MAS, one of the authors has encountered one
case (FRS).
Hyperparathyroidism
While there have been a number of reports of FD/MAS
in association with hyperparathyroidism [57-61], in none
of these cases was there molecular confirmation, and in
the one report where there was a very thorough effort to
show molecular confirmation, there was none [62]. This
led the authors to conclude that the association of pri-
mary hyperparathyroidism with FD/MAS was chance and
that hyperparathyroidism did not represent a molecu-
larly-driven association. Furthermore, in reconsidering
some of the cases in light of new information, there is a
question as to whether the disease described was FD or
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JT, the osseous lesion is a fibroosseous lesion with signifi-
cant histopathological similarities to FD, and confusion
with FD is not difficult. In addition, our current under-
standing of the molecular regulation of parathyroid func-
tion and parathyroid neoplasms does not predict that an
activating mutation in Gsa would lead to hyperparathyr-
oidism or a parathyroid adenoma. For these reasons,
most investigators today conclude that hyperparathyroid-
ism should not be considered to be part of the spectrum
of FD/MAS.
Neuropsychiatric
While there has been passing, ill-defined mention of
“mental retardation” in association with FD/MAS [63],
the most thorough chronicle of a possible association
between FD/MAS and any neuropsychiatric problems
was the evaluation of the NIH cohort by Brown et al [32].
In this study a number of findings were seen including
learning and speech disorders, such as speech apraxia,
and global developmental delay. While these findings
were seen in approximately 9% of the cohort as a whole,
they were found in 44% of the subjects who had had
Cushing’s syndrome, indicating that Cushing’s syndrome
is a significant risk factor for neuropsychiatric findings in
patients with FD/MAS. As Cushing’ss y n d r o m ei si n v a r i -
ably found in the neonatal period in MAS, it suggests
that in utero exposure to high levels of cortisol may be
deleterious to brain development. That said it is also pos-
sible that Cushing’ss y n d r o m ei nM A Sm a yb eam a r k e r
for widespread distribution of the gsp mutation and the
presence of neuropsychiatric symptoms is a manifesta-
tion of central nervous system involvement. In several
papers from the Abel laboratory in which the Q227L
activating mutation of Gsa (Q227L), a mutation that is
also an activating mutation functionally similar to the
R201C/H mutations that cause FD/MAS, was targeted to
the central nervous system of mice, the animals devel-
oped a spectrum of neuropsychiatric findings including
learning disorders [64-70]. One of the more striking find-
ings seen in these mice was the counterintuitive finding
that treatment with phosphodiesterase inhibitors seemed
to reverse the phenotype. Phosphodiesterases breakdown
cAMP, and given that the evidence thus far that much of
the pathophysiology of FD/MAS is the direct effect of
excess cAMP, one would assume that inhibition of
cAMP breakdown would exacerbate, not treat, symptoms
of gsp expression. Clearly there is much more to learn.
Summary
From this review, it is clear that the spectrum of extraske-
letal manifestations that can be found in MAS is broad –
as broad as the tissue distribution of Gsa expression.
While clinicians should consider that almost any finding
seen in association with FD/MAS may be the result of tis-
sue-specific gsp expression, the majority of the extraskele-
tal manifestations of MAS are confined to those listed in
Table 1. While effective treatments for FD remain elusive,
most of the conditions listed in Table 1 are readily amen-
able to treatment. Given that many of these conditions
will worsen the FD if untreated, it is important to suspect,
screen for, and treat these extraskeletal manifestations.
This information in this review was presented as part of
the Proceedings of the International Meeting on Fibrous
Dysplasia/McCune-Albright Syndrome and Cherubism at
the National Institutes of Health in Bethesda, Maryland
October 3-5, 2010. MTC, FRS and EE have drafted the
manuscript. All authors were involved in the critical
review of the manuscript. All authors read and approved
the final manuscript.
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